Insmed (INSM) Total Current Liabilities (2010 - 2026)
Insmed (INSM) posted quarterly Total Current Liabilities of $361.0 million for Q1 2026, up 50.9% year-over-year from $239.2 million in Q1 2025, and down 23.01% quarter-over-quarter from $468.9 million in Q4 2025.
Insmed (INSM) Total Current Liabilities (2010 - 2026) Analysis & Trends
Insmed's Total Current Liabilities history runs 17 years deep, the most recent figure standing at $361.0 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 50.9% year-over-year to $361.0 million; the TTM figure through Mar 2026 stood at $361.0 million (up 50.9% YoY), while the FY2025 annual figure was $468.9 million, up 57.59% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $361.0 million, down from $468.9 million in the prior quarter.
- The five-year high for Total Current Liabilities was $524.2 million in Q2 2024, with the low at $113.8 million in Q2 2022.
- The 5-year median for Total Current Liabilities is $239.2 million (2025), against an average of $275.4 million.
- The sharpest annual moves came in 2024 and 2025: Total Current Liabilities soared 156.61% in 2024, then slumped 43.16% in 2025.
- Insmed's Total Current Liabilities stood at $190.2 million in 2022, then advanced by 18.6% to $225.6 million in 2023, then soared by 31.87% to $297.5 million in 2024, then surged by 57.59% to $468.9 million in 2025, then decreased by 23.01% to $361.0 million in 2026.
- Business Quant data shows INSM's Total Current Liabilities at $361.0 million in Q1 2026, $468.9 million in Q4 2025, and $417.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | 283.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 438.74 Mn |
| Mar 31, 2026 | 361.01 Mn |
| Dec 31, 2025 | 468.87 Mn |
| Sep 30, 2025 | 417.21 Mn |
| Jun 30, 2025 | 311.68 Mn |
| Mar 31, 2025 | 239.23 Mn |
| Dec 31, 2024 | 297.53 Mn |
| Sep 30, 2024 | 259.19 Mn |
| Jun 30, 2024 | 524.15 Mn |
| Mar 31, 2024 | 420.86 Mn |
| Dec 31, 2023 | 225.63 Mn |
| Sep 30, 2023 | 196.73 Mn |
| Jun 30, 2023 | 204.26 Mn |
| Mar 31, 2023 | 187.98 Mn |
| Dec 31, 2022 | 190.24 Mn |
| Sep 30, 2022 | 137.65 Mn |
| Jun 30, 2022 | 113.82 Mn |
| Mar 31, 2022 | 125.25 Mn |
| Dec 31, 2021 | 135.17 Mn |
| Sep 30, 2021 | 112.50 Mn |